Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Silence Therapeutics (SLN) over the last 2 years, with Sep 2025 value amounting to $141.7 million.

  • Silence Therapeutics' Shares Outstanding (Diluted Average) fell 22.76% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 22.76%. This contributed to the annual value of $138.8 million for FY2024, which is 0.25% up from last year.
  • As of Q3 2025, Silence Therapeutics' Shares Outstanding (Diluted Average) stood at $141.7 million, which was up 0.00% from $141.7 million recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Shares Outstanding (Diluted Average) peaked at $183.5 million during Q3 2024, and registered a low of $113.3 million during Q4 2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $153.7 million, with a median of $141.7 million in 2025.
  • In the last 5 years, Silence Therapeutics' Shares Outstanding (Diluted Average) grew by 21.91% in 2023 and then fell by 22.76% in 2025.
  • Over the past 4 years, Silence Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $113.3 million in 2022, then increased by 21.91% to $138.1 million in 2023, then climbed by 0.46% to $138.8 million in 2024, then declined by 22.76% to $141.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $141.7 million in Q3 2025, compared to $141.7 million in Q2 2025 and $141.7 million in Q1 2025.